Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
427 Views
Emedinexus 03 April 2025
The U.S. Food and Drug Administration (FDA) has approved Yorvipath (palopegteriparatide) for subcutaneous use in adults with hypoparathyroidism. This treatment addresses the insufficient production of parathyroid hormone, which can lead to low calcium levels.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}